Trial Profile

A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EP 0042 (Primary) ; Antineoplastics
Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; First in man
Sponsors Ellipses Pharma

10 Dec 2024 Results (n=46) assessing final data from the dose escalation and optimization cohorts from a Phase I/IIa study of EP0042, presented at the 66th American Society of Hematology Annual Meeting and Exposition.
02 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
02 Jan 2024 Planned primary completion date changed from 1 Sep 2023 to 1 Oct 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com